
Peter De Cruz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4023521/publications.pdf Version: 2024-02-01



DETED DE CDIIZ

#	Article	IF	CITATIONS
1	Crohn's disease management after intestinal resection: a randomised trial. Lancet, The, 2015, 385, 1406-1417.	13.7	475
2	Development of the Lémann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease. Gastroenterology, 2015, 148, 52-63.e3.	1.3	257
3	Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery. Gastroenterology, 2015, 148, 938-947.e1.	1.3	241
4	Systematic review: predicting and optimising response to antiâ€ <scp>TNF</scp> therapy in Crohn's disease – algorithm for practical management. Alimentary Pharmacology and Therapeutics, 2016, 43, 30-51.	3.7	238
5	Association between specific mucosaâ€associated microbiota in Crohn's disease at the time of resection and subsequent disease recurrence: A pilot study. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 268-278.	2.8	137
6	Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in highâ€risk patients – a POCER study analysis. Alimentary Pharmacology and Therapeutics, 2015, 42, 867-879.	3.7	115
7	EHealth Technologies in Inflammatory Bowel Disease: A Systematic Review. Journal of Crohn's and Colitis, 2016, 10, 1103-1121.	1.3	106
8	Microbial Factors Associated with Postoperative Crohn's Disease Recurrence. Journal of Crohn's and Colitis, 2017, 11, 191-203.	1.3	86
9	Mobile Phone Apps for Inflammatory Bowel Disease Self-Management: A Systematic Assessment of Content and Tools. JMIR MHealth and UHealth, 2016, 4, e13.	3.7	73
10	Review article: the practical management of acute severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2016, 43, 482-513.	3.7	72
11	Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis. Journal of Crohn's and Colitis, 2016, 10, 979-988.	1.3	56
12	Perspectives of paediatric and adult gastroenterologists on transfer and transition care of adolescents with inflammatory bowel disease. Internal Medicine Journal, 2014, 44, 490-496.	0.8	47
13	Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Alimentary Pharmacology and Therapeutics, 2020, 52, 1551-1562.	3.7	38
14	Predicting response after infliximab salvage in acute severe ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1347-1352.	2.8	37
15	Postoperative recurrence of Crohn's disease: impact of endoscopic monitoring and treatment stepâ€up. Colorectal Disease, 2013, 15, 187-197.	1.4	34
16	Effect of Intestinal Resection on Quality of Life in Crohn's Disease. Journal of Crohn's and Colitis, 2015, 9, 452-462.	1.3	30
17	Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, 166-168.	1.3	29
18	eHealth for inflammatory bowel disease self-management – the patient perspective. Scandinavian Journal of Gastroenterology, 2017, 52, 1-8.	1.5	26

Peter De Cruz

#	Article	IF	CITATIONS
19	Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease. Internal Medicine Journal, 2016, 46, 266-273.	0.8	22
20	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 653-661.	1.3	22
21	Luminal microbiota related to Crohn's disease recurrence after surgery. Gut Microbes, 2020, 11, 1713-1728.	9.8	22
22	Review article: a practical approach to the clinical management of NSAID enteropathy. Scandinavian Journal of Gastroenterology, 2017, 52, 1-7.	1.5	21
23	Design considerations for an eHealth decision support tool in inflammatory bowel disease selfâ€management. Internal Medicine Journal, 2018, 48, 674-681.	0.8	20
24	Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 318-331.	8.1	20
25	Clinicians' adherence to international guidelines in the clinical care of adults with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2017, 52, 536-542.	1.5	19
26	Activity of Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis Predicts Poorer Clinical Outcomes. Inflammatory Bowel Diseases, 2020, 26, 1901-1908.	1.9	18
27	Clinical decision support improves quality of care in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2019, 49, 1040-1051.	3.7	16
28	Cerebral venous thrombosis associated with ulcerative colitis. Internal Medicine Journal, 2008, 38, 865-867.	0.8	15
29	Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1079-1100.	3.0	14
30	Mo1878 Comparison of Accelerated Infliximab Induction vs Standard Induction Treatment in Acute Severe Ulcerative Colitis. Gastroenterology, 2016, 150, S803.	1.3	13
31	Endoscopic Prediction of Crohn's Disease Postoperative Recurrence. Inflammatory Bowel Diseases, 2022, 28, 680-688.	1.9	13
32	Non-invasive Serological Monitoring for Crohn's Disease Postoperative Recurrence. Journal of Crohn's and Colitis, 2022, 16, 1797-1807.	1.3	10
33	Examination of the relationship between disease activity and patientâ€reported outcome measures in an inflammatory bowel disease cohort. Internal Medicine Journal, 2018, 48, 1234-1241.	0.8	9
34	Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study. Journal of Medical Internet Research, 2021, 23, e15946.	4.3	9
35	A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive. Inflammatory Bowel Diseases, 2021, 27, 1909-1918.	1.9	9
36	Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 226-231.	2.8	8

Peter De Cruz

#	Article	IF	CITATIONS
37	Health care costs associated with Australian tertiary inflammatory bowel disease care. Scandinavian Journal of Gastroenterology, 2017, 52, 851-856.	1.5	5
38	Tofacitinib Is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1302-1303.	4.4	5
39	Hepatic portal venous gas in Crohn's disease. BMJ Case Reports, 2014, 2014, bcr2014206244-bcr2014206244.	0.5	5
40	A framework to support quality of care for patients with chronic intestinal failure requiring home parenteral nutrition. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 567-576.	2.8	3
41	New models of care in IBD in changing times. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 40-41.	2.8	2
42	Letter: infliximab induction regimens in steroidâ€refractory acute severe colitis—a propensity score analysis. Alimentary Pharmacology and Therapeutics, 2020, 51, 665-666.	3.7	2
43	Letter: how can we reduce mortality in elderly patients with acute severe ulcerative colitis?. Alimentary Pharmacology and Therapeutics, 2020, 51, 1444-1445.	3.7	2
44	Pneumatosis cystoides intestinalis (PCI) in a patient with undiagnosed systemic sclerosis. BMJ Case Reports, 2018, 2018, bcr-2018-225175.	0.5	2
45	Reply. Gastroenterology, 2015, 148, 1475-1476.	1.3	1
46	Letter: dose optimising infliximab in acute severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2017, 45, 1169-1170.	3.7	1
47	Letter to the Editor: Antibiotic Cocktail for Pediatric Acute Severe Colitis and the Microbiome: The PRASCO Randomized Controlled Trial. Inflammatory Bowel Diseases, 2020, 26, e41-e41.	1.9	1
48	P302 Serum IL-6 is associated with treatment refractoriness in acute severe ulcerative colitis. Journal of Crohn's and Colitis, 2021, 15, S331-S331.	1.3	0
49	P172 Examining dysplasia surveillance in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis - a real world experience. Journal of Crohn's and Colitis, 2022, 16, i242-i242.	1.3	0